Dataset from A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN 1501)

The study is a Phase II randomized, open label, multicenter trial designed to identify
whether sirolimus is a potential alternative to prednisone as an up-front treatment for
patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk
stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as
well as a novel BMT CTN developed acute GVHD biomarker test.